2024.08.19
Publisher：
times
Famciclovir 0.25g Tablets and Diclofenac Sodium 25mg GR Tablets (MAH: Hangzhou Muyuan Pharma Co., Ltd.) manufactured by Huayi have been approved for marketing by the NMPA!
Famciclovir
Famciclovir is a prodrug of penciclovir, which rapidly converts to penciclovir after oral administration and maintains a relatively long half-life within cells. Its mechanism of action is the same as that of acyclovir, but its bioavailability is higher than that of acyclovir, allowing for lower dosing frequency and dosage compared to acyclovir. This product is primarily used for patients with normal immune function and is contraindicated in those allergic to famciclovir or penciclovir, as well as nursing mothers. Caution is advised for use in pregnant women and those with renal impairment.
Diclofenac Sodium GR Tablets
Diclofenac Sodium GR Tablets contain diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID) known for its significant anti-inflammatory and analgesic effects. Compared to other NSAIDs, it offers stronger anti-inflammatory action and higher safety. At present, it has become one of the most widely used NSAIDs globally.
With years of expertise and production capabilities, Huayi has gained the trust of customers. We always adhere to strict standards and requirements to ensure compliance of drug manufacturing process and controllable drug quality, meeting the rigorous demands of our customers. Our close collaboration with Muyuan Pharma, built on a shared vision and solid foundation of trust, has successfully facilitated the products approved by the NMPA! Looking forward to more cooperation with Muyuan Pharma in the future.
By virtue of its deep cultivation in the pharmaceutical field and continuous and vigorous investment in production, Huayi consistently provides our customers with high-efficient, high-quality, cost-controllable and reliable services in R&D and production to empower our clients and foster mutual development!
